CSIR Director General Dr. N. Kalaiselvi visited AMTZ in Visakhapatnam to witness the rapid evolution of India's medical technology sector. She announced unprecedented access to all 37 CSIR labs for MedTech startups.

  • CSIR DG Dr. N. Kalaiselvi inspected the MedTech ecosystem at AMTZ.
  • Inaugurated the expanded 1-lakh sq. ft. 'Medi Valley' incubation platform.
  • Announced that all 37 CSIR laboratories are open to support AMTZ startups.
  • Laid the foundation stone for SS Medical Systems' indigenous manufacturing expansion.

VISAKHAPATNAM: In a significant move to bolster India's healthcare manufacturing capabilities, Dr. N. Kalaiselvi, Director General of the Council of Scientific and Industrial Research (CSIR) and Secretary of the Department of Scientific and Industrial Research (DSIR), visited AMTZ on Tuesday. The visit aimed to witness the cutting-edge developments shaping the next phase of the nation's MedTech landscape.

During her visit, Dr. Kalaiselvi engaged in high-level discussions with Dr. Jitendra Sharma, MD & Founder CEO of AMTZ, and toured several prominent MedTech enterprises, including Pyramed, Molbio Diagnostics, Transasia Bio-Medicals, and Electra. These interactions underscored the growing synergy between research institutions and industrial leaders.

Read Also:Dyson V16 Piston Animal Review: Is the Extra Power Worth the Premium Price?

Expansion of Medi Valley Incubation

A major highlight of the visit was the inauguration of the expanded Medi Valley, AMTZ's specialized MedTech incubation platform. Supported by NITI Aayog, the facility has expanded into a massive 1-lakh square foot tower. This infrastructure is designed to accelerate the lifecycle of medical innovations, allowing startups to transform ideas into functional prototypes within six months and secure regulatory clearances within a year.

What Dr. Jitendra Sharma has built at AMTZ is truly remarkable—a complete ecosystem where innovation, research, manufacturing and entrepreneurship converge.

Driving Indigenous Manufacturing

The visit also included the foundation stone ceremony for SS Medical Systems (I) Pvt. Ltd., a company poised to significantly impact indigenous MedTech manufacturing. Their proprietary OptiMaser technology has already seen widespread adoption, with over 55,000 installations across India, demonstrating the scalability of local innovations.

BozokMedia analysis shows that the integration of CSIR's vast research network with AMTZ's manufacturing prowess creates a formidable barrier against global import dominance. Dr. Kalaiselvi emphasized that to strengthen startup-research linkages, all 37 CSIR laboratories will be accessible to AMTZ-based startups for advanced research and technical support.

Why This Matters

As India strives toward the goal of Viksit Bharat 2047, reducing dependency on imported medical devices is critical. The collaboration between CSIR and AMTZ provides a blueprint for how public-private partnerships can drive high-tech manufacturing and entrepreneurial success on a global scale.

Did You Know?: The Medi Valley incubation platform is specifically structured to help startups navigate the complex regulatory landscape of medical devices in record time.

Frequently Asked Questions

1. How does the CSIR-AMTZ collaboration benefit startups?
Startups gain direct access to 37 specialized CSIR laboratories for R&D and technical validation.

2. What is the role of NITI Aayog in this ecosystem?
NITI Aayog supports the Medi Valley incubation platform to foster a robust MedTech startup culture.